COL6A1 and neuromuscular disease: To test our gene editing strategy, we nucleofected the constructs into primary dermal fibroblast cells obtained from four independent patients carrying the COL6A1 c.868G>A (G290R) variant (Pt1 to Pt4), and from one non-neuromuscular disease patient as a control (Ctrl).